Physician profile
Fernando A Laracuente
NPI 1407378128
$1,803.91
in general payments reported to CMS, 2019-2025
18 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Psychiatric/Mental Health, Child & Family provider received nationally (typical 2025 total: $178).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,150 · 2022: $180 · 2023: $176 · 2024: $196 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $388.13 | 2021 | |
| Ironshore Pharmaceuticals INC. | $242.79 | 2021-2024 | Jornay Pm |
| Aquestive Therapeutics, INC. | $230.74 | 2021-2022 | |
| Adlon Therapeutics L.P. | $187.77 | 2021 | |
| Almatica Pharma LLC | $127.32 | 2024-2025 | Loreev Xr |
| Aprecia Pharmaceuticals, LLC | $108.43 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.23 | 2021 | |
| Neurelis, INC. | $76.49 | 2021 | |
| Abbvie INC. | $73.81 | 2024-2025 | |
| Alkermes, INC. | $54.21 | 2023 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $45.15 | 2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $41.76 | 2021-2022 | |
| Eisai INC. | $27.25 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $26.51 | 2024 | Ingrezza |
| Sumitomo Pharma America, INC. | $23.93 | 2023 | Aptiom |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.38 | 2023 | Repatha, Otezla |
| Endo Pharmaceuticals INC. | $18.43 | 2022 | |
| Corium, LLC | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Laracuente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.